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Background: Despite the advances of current optimal treatment of atherosclerotic disease, the incidence of events 
after acute coronary syndrome (ACS) remains high.  Colchicine, with its well-established pleiotropic anti-inflam-
matory effects, may inhibit NLRP3 inflammasome, a key mediator in atherosclerosis-associated inflammation 
(AAI) thus reducing systemic inflammation. NRLP3 inflammasome activation inside leukocytes (mainly 
monocytes and neutrophils) is precipitated by cholesterol crystals that are present in all atherosclerosis stages. 
Subsequent activation of pro-inflammatory cytokines such as interleukin-1β and interleukin-18 will follow. These 
cytokines are the crucial inflammatory pathway mediators that promote the formation of plaque and instability 
in the inflammatory cascade.
Objective: This review will elaborate on the function of immune cells in atherosclerosis, explain the mechanisms 
of NLRP3 inflammasome activation in the context of AAI, and address the possible role of colchicine specifically 
targeting NLRP3 inflammasome and its concomitant downstream mediators in ACS, and provide an overview of 
current or ongoing studies produced in this area.
Discussion : NRLP3 inflammasome activation inside leukocytes (mainly monocytes and neutrophils) is precipitat-
ed by cholesterol crystals that are present in all atherosclerosis stages. Subsequent activation of pro-inflammatory 
cytokines such as interleukin-1β and interleukin-18 will follow. These cytokines are the crucial inflammatory 
pathway mediators that promote the formation of plaque and instability in the inflammatory cascade. A potential 
advantage of a medication acting through an inflammatory milieu found in atherosclerotic lesions has recently 
become the need for novel therapeutic options. Colchicine, with its well-established pleiotropic anti-inflammato-
ry effects, may inhibit NLRP3 inflammasome, a key mediator in atherosclerosis-associated inflammation (AAI) 
thus reducing systemic inflammation.
Conclusion: Colchicine is a safe and reliable medication for ACS patients, alongside reveal various benefit in 
reducing inflammation through inhibition of NLRP3 Inflammasome.
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 Inflammation in acute coronary syndrome (ACS) occurs in 
multiple pathways. Nucleotide-binding Oligomerization Domain-Like 
Receptors, Pyrin Domain-Containing 3 (NLRP3) inflammasome has 
been known to serve as a key mediator in atherosclerotic plaque forma-
tion, progression, and destabilization.1 The risk of recurrent major 
cardiovascular events (up to 20% at 3 years) is increased in patients 
with an index ACS, indirectly explained by lingering coronary inflam-
mation at the culprit and non-culprit sites after prior ACS episode, 
despite current guideline-based medical treatment.2 Colchicine is a 
safe, simple, low-cost, yet potent anti-inflammatory medication widely 
known for the treatment of acute gout, and other cardiac conditions 
such as pericarditis, which may represent another potential role of 
inflammation in ACS. The mechanisms of colchicine in manipulating 
leukocytes include its ability to suppress NLRP3 inflammasome through 
impairment of mitochondrial colocalization of inflammasome proteins, 
disruption of microtubule formation, and inhibition of inflammasome 
activation and cytokine production.3 This review outlines the action of 
colchicine as a secondary preventive agent after index ACS and 
elucidates an overview of trials currently develop this far.
2. NLRP3 Inflammasome and Inflammation in ACS
 The pathogenesis of the development, growth, and rupture 
of atherosclerotic plaque is primarily linked to inflammation, contribut-
ing to acute clinical incidents. Both innate and adaptive immune 
systems are involved in inflammation. Mononuclear phagocytes (mono-
cytes and macrophages) play a significant role in the inflammatory 
response in the whole atherosclerotic disease process, present from 
atherogenesis, plaque formation, destabilization, and rupture, and 
subsequently in the healing process after acute infarction as the key 
effectors. Monocyte recruitment started in the early stages of athero-
sclerosis, then continues in mature plaque formation, suggesting 
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 continuous activation in many phases of plaque develop-
ment. In the early phases, phagocytosis of oxidized Low-Density 
Lipoproteins (ox-LDL) by macrophages mediated by scavenger receptor 
A and CD36 as a membrane receptor, promoting secretion of several 
cytokines, such as interleukin-1β (IL-1β) and TNF-α, thus transform 
itself into foam cells. Monocytes/macrophages activation further 
release metalloproteinases, which destabilize the plaque through the 
weakening of collagen-mediated fibrous cap in the later phase of 
plaque development, which in turn may result in plaque rupture and 
subsequently, Myocardial Infarction.2
 To respond to harmful or pathogenic signals, the innate 
immune response relies heavily on Pattern-Recognition Receptors 
(PRRs). Inflammasomes are one such cytoplasmic PRR. It is a Pyrin 
domain-containing 3 Nucleotide-binding Oligomerization Domain 
(NOD)-like receptor (or NLR for short) (NLRP3; which also named 
NALP3 or cryopyrin). In all myeloid cells, including eosinophils, neutro-
phils, and monocytes, NLRP3 is present.2,4
 Formerly recognized as a type of Toll-like receptor (TLR) 
NLRP3 is part of the family of NOD-like receptors (NLR), while 
transmembrane innate immune sensors are TLRs. NLRP3 is not a form 
of TLR, whereas both TLR and NLR are PRRs containing a leucine-rich 
repeat domain. TLRs and NLRs differ partly in downstream signaling 
pathways, activation mechanism. cellular localization, and domain 
composition.4 The NLRP3 inflammasome comprises 3 main compo-
nents i.e.: 1) NLRP3 receptor (a type of TLR); 2) Caspase-Containing 
and Activation Recruitment Domain (CARD) Apoptosis-Associated 
Speck-Like Protein-ASC as an adaptor protein; and 3) Caspase-1 as the 
effector cysteine protease. However, ASC plays a role as the link 
between NLRP3 and caspase-1 since it lacks a pyrin domain.5
 Activation of inflammasome complex is explained following 
increase reactive oxygen species (ROS) and large molecule damage-as-
sociated molecular pattern (DAMP) exposure, such as cholesterol 
crystals. Inefficient removal after phagocytosis of DAMP results in 
lysosome destabilization and subsequent rupture. This later releases 
cathepsin B into the cytoplasm and stimulates the development of the 
inflammasome complex and its inflammatory cytokines downstream. 
Normally, inflammatory components (NLRP3 receptors, caspase-1, and 
ASC) and their substrates (pro-IL-1β and pro-IL-18) are identified at 
very low levels. Hence, inflammasome activation requires a two-step 
process. First, initial priming is triggered by TLR stimuli or monocyte 
interaction, as it will be elucidated later, which leads to the nuclear 
factor kappa B (NF-kB) activation, which promotes inflammasome 
components transcription. Second, additional stimuli start the assembly 
of inflammasome and activation of Caspase-1, resulting in the produc-
tion of cytokine.5,6
 Activation of inflammasome has been linked with damage of 
myocardium following infarction and subsequent reperfusion. A 
previous clinical study of ACS patients demonstrated a higher level of 
NLRP3, cathepsin-B, IL-18, and IL-1β compared to normal controls.7 A 
previous in vivo analysis found that the ASC and caspase-1 deficiency in 
mice models led to a decline in inflammation, duration of infarction, 
and myocardial fibrosis following ischemia.2 Activation of inflam-
masome appears to be the main mechanism to explain the 
monocytes/macrophages and PMN mutual interaction. It is understood 
that PMN granule secretion draws monocytes to the location of athero-
sclerotic plaque, further encouraging plaque progression and vulnera-
bility. Besides, neutrophils may stimulate monocyte production of IL-1
β and IL-18, key cytokines that have been linked to atherogenesis. IL-1
β and IL-18 are produced as inactive forms and need the cleavage of 
caspase-1 mediated by NLRP3 inflammasome to create the active form. 
Either IL-1β or IL-18 enhances chemokines release that further attracts 
neutrophils into the atherosclerotic unstable plaques.8
 Martinez et al. (2015) demonstrated that in atherosclerosis 
patients inflammasome end-products IL-1β and IL-18 are expressed 
locally. Levels of these two cytokines depend on the activity of the 
disease. ACS patients exhibited the highest trans-coronary gradients, 
The second highest gradient in patients with stable angina, and the 
lowest gradient in patients with non-obstructive coronary artery 
disease. IL-1β can also influence post-MI cardiac remodeling in addition 
to its role in atherosclerosis. Inhibition of IL-1β involvement inhibits 
post-MI apoptosis and fibrosis, thereby improving myocardial malfunc-
tion and negative remodeling.1
3. NLRP3 Inflammasome Inhibition Function of Colchicine
 Colchicine is a low-cost drug that is safe and globally 
available. Colchicine is used mostly as gouty arthritis and treatment for 
 
5
Figure 1. Inflammatory pathway in acute coronary syndrome.4
 Infiltration of low-density lipoprotein (LDL) and formation of macrophage foam cells in arterial wall leading to the release of pro-inflammatory cytokines, which 
further contributes to plaque destabilization and subsequent rupture, presenting as an acute coronary syndrome. 
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familial Mediterranean fever. Colchicine is commonly recommended in 
cardiology as an anti-inflammatory treatment for both chronic and 
acute pericarditis. Colchicine has a potent but relatively safe anti-in-
flammatory function in contrast to other immunosuppressive agents, 
which attracts its implementation as a medication for inflammatory 
diseases.2 Colchicine acts on mitosis by promoting depolymerization of 
the microtubule by binding to tubulin. Colchicine thus inhibits many 
microtubule functions: chromosome pair separation during mitosis, 
leucocyte ameboid movements including exocytosis and phagocytosis. 
Colchicine inhibits COX-2 production as well as TNF-alpha, leukotriene 
B4, prostaglandin E2, and TxA2 production. Reducing the expression of 
both E and P-selectin, colchicine disrupts adhesion of PMN to endothe-
lium which interrupts neutrophil migration, thus inhibits inflammation, 
even at low doses.9 
 
 More recently, NLRP3 inflammasome activity inhibition has 
been identified to be associated with a novel mechanism of action, thus 
suppressing cytokine output (IL-1β and IL-18) and neutrophil 
migration. Another presumed mechanism of action by which colchicine 
may inhibit the activation of inflammasome NLRP3 is the suppression of 
pyrin (MEFV) gene expression, a gene that codes for the NLRP3 
receptor, impairing the assembly of NLRP3 inflammasome. It is known, 
recently, that monocyte caspase-1 inhibition is the colchicine mecha-
nism of action in ACS patients.2 In contrast, Misawa et al. (2013) 
demonstrated colchicine inhibition of intracellular ASC transport by 
blocking co-localization and action of NLRP3 inflammasome proteins.10 
Colchicine impairs the mobilization of CARD – ASC, to the endoplasmic 
reticulum from the mitochondria. This in turn prevents its co-localiza-
tion with the rest of the inflammasome complex.1 Colchicine induces 
effective inhibition of pore formation caused by P2X7 (which is the key 
step in the inflammasome response of NLRP3 to ATP), resulting in 
lower levels of IL-1β and ROS.2
 Considering these novel effects on the NLRP3 inflammasome, 
also the well-known actions on neutrophil migration, microtubular 
function, and colchicine has arisen as a plausible future approach for 
the treatment of diseases mediated by atherosclerosis, particularly 
acute coronary syndromes.
PROSPECT Trial demonstrated the additional therapy is crucial in 
patients with ACS by assessing the natural history of 697 patients 
hospitalized with ACS who underwent successful uncomplicated 
percutaneous transluminal coronary angioplasty (PTCA). After a 
follow-up period of 3 years, the cumulative risk of MACE was <1%, 
15%, and 20.4%  at 30 days, 12 months, and  3 years respectively. 
almost half of the events related to the progression of non-culprit 
lesions (NCL) in the first year. However, beyond the first-year clinical 
events were twice as likely to relate to the NCL progression. NCL had a 
large lipid-rich vulnerable plaque burden and a thin fibrous cap when 
assessed by intravascular ultrasound. NCL often contains cholesterol   
crystals in high concentrations, which may be potential in NLRP3 
inflammasome activation. Colchicine has been shown to prevent and 
dampen this mechanism.11
 In 532 patients with healthy coronary artery disease, the Low 
Dose Colchicine for Secondary Prevention of Cardiovascular Disease 
Study (LoDoCo Trial) stated that long-term colchicine treatment (0.5 
mg/day) resulted in a 3-year improvement in acute events relative to 
no colchicine treatment.1,12 Based on this result, many trials are 
developed to determine the action of colchicine in the ACS setting, 
regarding its anti-inflammatory properties. Hence, the Low Dose 
Colchicine after Myocardial Infarction (LoDOCo-MI) Study was 
conducted as a sequel to the previous trial which commences the subset 
of AMI patients. This was a randomized, double-blind study of 237 
acute MI patients using low-dose colchicine (0.5 mg daily) or matching 
placebo. The primary outcome in this study was the proportion of 
patients with a residual high sensitivity C-reactive protein (CRP) level 
≥ 2 mg/L after thirty days of therapy. It was shown by LoDoCo-MI that 
low-dose colchicine was safe and quite well tolerated. However, the 
likelihood of achieving a lower absolute CRP level in 30 days or CRP 
level < 2 mg/L after an acute infarction was not significantly 
increased.12
 The Colchicine Cardiovascular Outcomes Trial (COLCOT 
Study) was performed over 4745 patients surviving 30 days after an 
acute MI. They were randomly divided into colchicine versus the 
placebo group, half in amount among each group. The primary 
endpoint was a major adverse cerebrocardiovascular event (MACCE) 
and urgent rehospitalization for angina leading to coronary revascular-
ization during 2-year follow-up. This study demonstrated that among 
patients with a recent myocardial infarction, low-dose colchicine at a 
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Figure 2. Two-signal activation of NLRP3 inflammasome.4 
Activation of the NLRP3 inflammasome requires both the initial priming step (left) and the following activation step (right). Priming of macrophages is provided by 
endogenous cytokines (IL-1 and TNF-α) and binding of PAMPs on damage large molecules to membrane-bound TLR. The second activation step involves a variety 
of stimuli, including intracellular oxLDL accumulation, PAMPs, and crystalloid particulates such as uric and cholesterol crystals. The NLRP3 inflammasome catalyzes 
the conversion of pro-caspase-1 to its active form, caspase-1, which then converts pro-IL-1β and pro-IL-18 into their bioactive, pro-atherogenic forms, IL-1β and 
IL-18. 
Heart Sci J 2020; 1(4): 4-8
Figure 3. Colchicine inhibition of the NLRP3 inflammasome.2 
At least four purported mechanisms of inhibition of the NLRP3 inflammasome 
by colchicine have been described. 1) Inhibition of MEFV gene resulting in 
Pyrin (receptor) inhibition; 2) inhibition of inflammasome cytoplasmic 
co-localization due to tubulin interference; 3) direct caspase-1 blockage; 4) 
inhibition of P2X7-mediated pore formation resulting in decreased Kþ efflux. 
The final result is inhibition of active form IL-1b (and probably IL-18) 
production.
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dose of 0.5mg daily led to a significantly lower risk of ischemic MACCE 
and urgent rehospitalization (5.5% and 7.1%, respectively) compared 
to placebo on top of contemporary optimal medical treatment (OMT). 
Time-to-Treatment Initiation (TTI) of low-dose colchicine within days 
0-3 after MI significantly reduces the risk of ischemic CV events by 48% 
compared to placebo, but not statistically significant within TTI days 
4-7 and days 8-30 after MI. This study elucidated a subgroup analysis 
of these population who underwent PCI (4408 patients) and revealed 
that administration of low-dose colchicine daily after PCI for MI 
reduced risk of MACCE and rehospitalization for urgent revasculariza-
tion (5.2% and 7.1%, respectively) compared to placebo. Early 
initiation of colchicine, within 3 days following PCI for an MI, reduced 
the risk of ischemic CV events by 40%, as well.13
 Colchicine was prescribed to 44 patients hospitalized for 
ST-segment elevation myocardial infarction (STEMI) in patients with 
acute myocardial infarction (COLIN trial) who were treated successful-
ly with the percutaneous coronary intervention (PCI). They were 
divided in half amount into colchicine (as an addition to optimal 
medical treatment) group versus control (conventional optimal medical 
treatment only) group. The treated group was given colchicine 1mg 
once daily for one month, with no loading dose. On admission, baseline 
CRP was taken and proceeded daily until discharge. During the index 
hospitalization, the CRP peak value was set as the primary endpoint. 
The outcome seen in this research was no significant difference in mean 
CRP peak value relative to the control group of colchicine administra-
tion.14
 A prospective randomized study - Anti-Inflammatory 
Treatment with Colchicine in Acute Myocardial Infarction: A Pilot 
Study, held by Defteros et al. (2015), was comparing the administra-
tion of colchicine or placebo for 5 days in 151 STEMI patients present-
ing ≤ 12 hours from pain onset (treated with primary PCI). The result 
demonstrated that the administration of oral colchicine (loading dose 
of 2 mg and continuing with 0.5mg twice daily) was correlated with 
smaller infarct size, as defined by a reduction in area under the curve of 
creatine kinase-MB and in infarct size on cardiac MRI, as well as a 
reduction in post-myocardial-infarction inflammatory markers such as 
neutrophil count and CRP which is known to be strongly related to 
infarct size.15
Robertson et al. (2016) studied 21 ACS patients who were randomized 
to oral colchicine (1mg followed by 0.5mg 1 hour later) or no treatment 
and compared with 9 untreated healthy control. NLRP3 inflammasome 
markers (pro-caspase-1 mRNA level and caspase-1 protein), IL-1β, and 
IL-18 levels were the key endpoints. In ACS patients, levels of IL-1β and 
IL-18 were slightly higher. Colchicine therapy in ACS patients substan-
tially lowered secreted and intracellular IL-1β levels reduced signifi-
cantly pro-caspase-1 mRNA levels and secreted caspase-1 protein levels 
relative to untreated patients. In ACS patients, Inflammasome-related 
cytokines are primed to be secreted by monocytes. Moreover, colchicine 
administered in short-term acutely and significantly inhibits the activity 
of monocyte caspase-1, thus reducing IL-1β monocyte secretion.16
 Martinez et al. (2015) studied 40 ACS patients, 33 with 
stable CAD, and 10 controls in a randomized control trial. Patients are 
grouped into either oral colchicine treatment (1mg followed by 0.5mg 
1 hour later) group or no colchicine group, 6 to 24 hours before DCA. 
IL-1β, IL-6, and IL-18 levels collected from the coronary sinus, aortic 
root (arterial), and lower right atrium (venous)  blood were the main 
endpoints. In ACS patients, coronary sinus levels of IL-1β, IL-6, and 
IL-18 were found to be substantially higher than arterial and venous 
levels. IL-1β, IL-6, and IL-18 transcoronary (coronary sinus-arterial) 
gradients were highly expressed in ACS patients and lowest in controls. 
Administration of colchicine in ACS patients markedly reduced trans 
coronary gradients of all cytokines by 40% to 88%. ACS patients exhibit 
an enhanced local cardiac synthesis of inflammatory cytokines, which 
are rapidly reduced by the short-term administration of colchicine.1 It 
has been suggested that the supposed mechanisms by which colchicine 
prevents the release of these inflammatory cytokines correlate with the 
inflammasome complex activation block explained above. Colchicine is 
indicated to exert its beneficial effects across various mechanisms on 
the inflammasome complex. For example, as seen in the previous 
report, it can rapidly suppress the assembly of the inflammasome 
complex, thereby exerting an acute effect. It may also have a transcrip-
tional effect, a mechanism related to longer exposure to the drug, 
which further impairs the synthesis of IL-1β and IL-18.
 The Acute Colchicine Administration Before PCI (COLCHI-
CINE-PCI Randomized Trial) was performed among 400 subjects who 
underwent PCI, which was randomized to acute preprocedural (1-2 
hours before PCI) oral administration of colchicine 1.8mg or placebo. 
The result demonstrated acute preprocedural administration of colchi-
cine attenuated the elevation of interleukin-6 and high-sensitivity 
C-reactive protein concentrations, but not the increase of IL-1β, 
24-hours after PCI when compared with placebo. Colchicine decreased 
inflammation 24-hours post-PCI (prevented a rise in inflammation 
during acute injury) but did not reduce the risk of PCI-related myocar-
dial injury or 30-days MACE when compared with placebo.17
 The latest on-going study, the Colchicine to Improve Cardio-
vascular Outcomes in ACS Patients (COPS Trial), included 795 patients 
hospitalized for ACS who have undergone diagnostic coronary angiog-
raphy (DCA) with >30% stenosis and have been treated with PCI or 
conservatively. The study population was classified into two groups, ie. 
colchicine plus OMT versus placebo plus OMT group. The former group 
was given an oral low dose of 0.5mg colchicine twice a day for 4 weeks 
followed by 0.5mg daily for 11 months. The primary composite 
endpoints included all-cause mortality, recurrent ACS, stroke, and 
urgent target vessel revascularization for angina were assessed during 
12-months, 2-year, and 5-year follow up. The result revealed that 
low-dose oral colchicine in addition to OMT during hospitalization and 
continued for 12-months was associated with a lower rate of the prima-
ry composite outcomes for at least 400 days after the index hospitaliza-
tion. Longer-term follow-up of the COPS cohort is planned.18
5. Conclusion
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The pathogenesis of atherosclerotic plaque formation, progression, and 
rupture is mainly associated with inflammation, leading to acute 
clinical events. Monocytes/macrophages and neutrophils are key 
effectors of the inflammation occurred during acute coronary 
syndrome. NLRP3 inflammasome, a pattern-recognition receptor, 
which commonly presents in myeloid cells, is found to play important 
role in atherosclerosis-mediated inflammation. NLRP3 inflammasome 
and the synthesis of its downstream inflammatory cytokines are activat-
ed following increase reactive oxygen species (ROS) and large 
molecule damage-associated molecular pattern (DAMP) exposure, such 
as large cholesterol crystals, found in the progression of atherosclerosis. 
Colchicine, an ancient anti-inflammatory drug, is known for its 
pleiotropic effects, which could inhibit the action of NLRP3 inflam-
masome and its downstream inflammatory cytokines through several 
mechanisms, either in patients with stable CAD or ACS. Many trials 
have been studied about the beneficial role of colchicine in the ACS 
settings, either in the short- or long-term benefit of its anti-inflammato-
ry properties as well as reducing the subsequent MACE. This review is 
directed to encourage future studies in favor of this ancient, yet recent-
ly re-emerging drug, to lower the rate of recurrent cardiovascular 
events and improve patient outcome.  
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